Polaris Market Research today announced findings from its latest report, projecting the global plasma protease C1-inhibitor market to grow from USD 3.51 billion in 2023 to USD 7.96 billion by 2032, at a CAGR of 9.6% from 2024 to 2032. The report profiles 10 leading companies across three market segments and five regions, with detailed market size, market share and market forecast analysis.

Analyst Commentary on Plasma Protease C1-Inhibitor Market Growth

“Growing diagnosis of hereditary angioedema and a strong clinical pipeline are the industry trends underpinning this market growth,” said the lead analyst at Polaris Market Research. “Opportunity lies in earlier detection, expanded indications and new oral and subcutaneous options that make long-term management easier for patients.”

Plasma Protease C1-Inhibitor Market Statistics at a Glance

• 2023 Market Size: USD 3.51 billion
• 2024 Estimated Size: USD 3.82 billion
• 2032 Projected Size: USD 7.96 billion
• CAGR (2024–2032): 9.6%
• Largest Region (2023): North America
• Leading Drug Class: C1-inhibitors; Leading Channel: Hospital pharmacies

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: The rising incidence and diagnosis of hereditary angioedema (HAE), increasing clinical trials and research initiatives, and rising healthcare expenditure are the primary forces behind the market’s expansion, alongside growing demand for effective rare disease therapies. A March 2024 article in the Journal of Cutaneous Immunology and Allergy indicated that approximately 1 in 50,000 people are affected by HAE, and improved awareness and genetic testing are leading to earlier detection and treatment. Orphan drug incentives, including expedited reviews, further encourage investment. In September 2022, CSL Behring K.K. received approval in Japan for Berinert S.C. Injection 2000 to prevent acute HAE attacks. The C1-inhibitor is a protein that regulates the complement and contact coagulation systems, helping prevent excessive inflammation and maintain hemostatic balance.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market

Market Restraint: The high cost of treatment remains a challenge for payers and patients.

Segment Highlights: C1-inhibitors, including C1-esterase and recombinant inhibitors, held the largest drug class share in 2023, supported by recombinant human C1 inhibitors that offer safer and more reliable options. Hospital pharmacies dominated distribution because of their role in acute care and specialist oversight of HAE treatment.

Competitive Landscape: Leading players are investing heavily in research and development, product launches, agreements, mergers and acquisitions, and collaborations to expand their global footprint. Manufacturing locally to reduce operating costs is a key strategy, and cost-effective offerings are increasingly important. Takeda concentrates on rare genetics and hematology, among other areas, while KalVista is advancing oral small-molecule protease inhibitors for HAE and other conditions.

Major Companies Covered: BioCryst Pharmaceuticals, Inc., CENTOGENE N.V., CSL, Fresenius Kabi, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Pharming, Sanquin, Shire plc and Takeda Pharmaceutical Company Limited.

Segments Covered: By Drug Class (C1-Inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Dosage Form (Lyophilised, Injectables), By Distribution Channel (Hospital, Retail and Online Pharmacies), By Region.

Recent Developments in the Plasma Protease C1-Inhibitor Market

• June 2024: KalVista Pharmaceuticals submitted a New Drug Application to the FDA for sebetralstat, an investigational oral plasma kallikrein inhibitor, as the first oral on-demand HAE treatment for patients aged 12 and older.
• May 2024: BioCryst presented real-world evidence at ISPOR 2024 showing reduced healthcare resource use among U.S. HAE patients after starting ORLADEYO (berotralstat).
• February 2023: Takeda presented new analyses, including the SPRING Study of TAKHZYRO in pediatric HAE patients, at the AAAAI Annual Meeting.
• June 2022: ORLADEYO emerged as the first oral, once-daily prophylactic therapy to prevent HAE attacks in patients aged 12 and older.

Regional Snapshot: North America Leads, Asia Pacific Expanding

North America held the dominant position in 2023, driven by high HAE prevalence, advanced healthcare infrastructure, a regulatory environment that speeds approvals, and strong research investment by regional pharmaceutical firms. Asia Pacific is witnessing substantial expansion through 2032, propelled by rising chronic inflammatory conditions, an aging population, the emergence of recombinant human inhibitors, and new entrants introducing innovative formulations and delivery techniques. Latin America and the Middle East & Africa complete the regional coverage, and country-level analysis is included in the full study.

Why It Matters for Buyers Evaluating the Plasma Protease C1-Inhibitor Market Forecast to 2032

For stakeholders researching the plasma protease C1-inhibitor market forecast and the top companies leading it, the underlying report benchmarks market share, company positioning and segment-level forecasts to support sourcing, partnership and investment decisions through 2032. Biopharmaceutical companies, hospital systems and investors can use the analysis to track HAE therapy innovation. The study also examines drivers, restraints, value chain dynamics and Porter’s Five Forces, helping decision-makers understand how treatment costs, orphan drug incentives and competitive intensity will shape opportunity.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

laundry-detergent-market

outsourced-semiconductor-assembly-and-test-market

global-paints-and-coatings-market

radiotheranostics-market

glp-1-analogues-market

multiparameter-patient-monitoring-market

vanillin-market

warehouse-automation-market

alginate-market